Advancements in the management of obesity: a review of current evidence and emerging therapies

References

• Chakhtoura M, Haber R, Ghezzawi M, et al. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. doi: 10.1016/j.eclinm.2023.101882
   PubMedGoogle Scholar
• Fruh SM. Obesity: risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29(S1):S3–S14. doi: 10.1002/2327-6924.12510
   PubMedGoogle Scholar
• Abarca-Gómez L, Abdeen ZA, Hamid ZA. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642. doi: 10.1016/S0140-6736(17)32129-3
   PubMed Web of Science ®Google Scholar
• Public Health England. Patterns and trends in adult obesity. [cited 2023 Mar 29]; Available from: https://fingertips.phe.org.uk/profile/national-child-measurement-programme/data#page/13/.
   Google Scholar
• Ahmad NN, Butsch WS, Aidarous S. Clinical management of obesity in women: addressing a lifecycle of risk. Obstet Gynecol Clin North Am. 2016;43(2):201–230. doi: 10.1016/j.ogc.2016.01.007
   PubMed Web of Science ®Google Scholar
• Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. doi: 10.1186/1471-2458-9-88
   PubMed Web of Science ®Google Scholar
• Collaborators GBDO. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
   PubMed Web of Science ®Google Scholar
• Dai H, Alsalhe TA, Chalghaf N, et al. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: an analysis of the global burden of disease study. PLOS Med. 2020;17(7):e1003198. doi: 10.1371/journal.pmed.1003198
   PubMed Web of Science ®Google Scholar
• Sarwer DB, Polonsky HM. The psychosocial burden of obesity. Endocrinol Metab Clin North Am. 2016;45(3):677–688. doi: 10.1016/j.ecl.2016.04.016
   PubMed Web of Science ®Google Scholar
• Angelidi AM, Belanger MJ, Kokkinos A, et al. Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to Gene Therapy. Endocr Rev. 2022;43(3):507–557. doi: 10.1210/endrev/bnab034
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203. doi: 10.4158/EP161365.GL
   PubMed Web of Science ®Google Scholar
• Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40–66. doi: 10.1159/000496183
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the american college of cardiology/american Heart Association Task Force on practice guidelines and the obesity society. J Am Coll Cardiol. 2014;63(25):2985–3023. doi: 10.1016/j.jacc.2013.11.004
   PubMed Web of Science ®Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. obes facts. Obes Facts. 2015;8(6):402–424. doi: 10.1159/000442721
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235–251. doi: 10.1037/amp0000517
   PubMed Web of Science ®Google Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604. doi: 10.1056/NEJMoa1105816
   PubMed Web of Science ®Google Scholar
• Bergmann NC, Davies MJ, Lingvay I, et al. Semaglutide for the treatment of overweight and obesity: a review. Diab Obes Metab. 2023;25(1):18–35. doi: 10.1111/dom.14863
   PubMed Web of Science ®Google Scholar
• Kushner RF. Weight loss strategies for treatment of obesity: lifestyle management and pharmacotherapy. Prog Cardiovasc Dis. 2018;61(2):246–252. doi: 10.1016/j.pcad.2018.06.001
   PubMed Web of Science ®Google Scholar
• Johnson S, Schwartz SM. Pharmacologic and pharmacodynamic equivalence of 2 formulations of orlistat. Clin Pharmacol Drug Dev. 2018;7(7):773–780. doi: 10.1002/cpdd.457
   PubMed Web of Science ®Google Scholar
• Jain SS, Ramanand S, Ramanand J, et al. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocr Metab. 2011;15(2):99–104. doi: 10.4103/2230-8210.81938
   PubMedGoogle Scholar
• Golay A, Laurent‐Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13(10):1701–1708. doi: 10.1038/oby.2005.208
   PubMedGoogle Scholar
• Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–2883. doi: 10.1001/jama.293.23.2873
   PubMed Web of Science ®Google Scholar
• Kujawska-Luczak M, Szulinska M, Skrypnik D, et al. The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance. J Physiol Pharmacol. 2018;69(5):737–745.
   Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814–822. doi: 10.1592/phco.22.11.814.33627
   PubMed Web of Science ®Google Scholar
• Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Invest Drugs. 2008;9(4):414–421.
   PubMedGoogle Scholar
• Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007;31(3):494–499. doi: 10.1038/sj.ijo.0803446
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diab Obes Metab. 2017;19(9):1242–1251. doi: 10.1111/dom.12932
   PubMed Web of Science ®Google Scholar
• Donath MY, Burcelin R. GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care. 2013;36(Suppl 2):S145–8. doi: 10.2337/dcS13-2015
   PubMedGoogle Scholar
• Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diab Obes Metab. 2018;20(3):610–619. doi: 10.1111/dom.13120
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–520. doi: 10.1172/JCI990
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5):R1541–4. doi: 10.1152/ajpregu.1999.276.5.R1541
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90. doi: 10.2337/dc08-1355
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. doi: 10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi: 10.1021/acs.jmedchem.5b00726
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Wegovy – summary of product characteristics. [cited 2023 Apr 20]; Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy.
   Google Scholar
• Health Canada. Wegovy – product monograph. [cited 2023 Apr 20]; Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101167.
   Google Scholar
• Medicines & Healthcare Products Regulatory Agency. Wegovy 2.4 Mg, solution for injection in Pre‐Filled pen – summary of product characteristics. [cited 2023 Apr 20]; Available from: https://mhraproducts4853.blob.core.windows.net/docs/04bd114b87aac3b439436d9317d836ef2b400ea9.
   Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi: 10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi: 10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–150. doi: 10.1001/jama.2021.23619
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. doi: 10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Semaglutide For Managing Overweight And Obesity. [cited 2023 Apr 28]; Available from: https://www.nice.org.uk/guidance/ta875/resources/semaglutide-for-managing-overweight-and-obesity-pdf-82613674831813.
   Google Scholar
• Knop FK, Aroda VR, Do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705–719. doi: 10.1016/S0140-6736(23)01185-6
   PubMed Web of Science ®Google Scholar
• Han W, Wang L, Ohbayashi K, et al. Glucose-dependent insulinotropic polypeptide counteracts diet-induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin-responsive and proopiomelanocortin neurons in the arcuate nucleus. Diab Obes Metab. 2023;25(6):1534–1546. doi: 10.1111/dom.15001
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Wysham C, Frífrías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. doi: 10.1016/S0140-6736(21)01324-6
   PubMed Web of Science ®Google Scholar
• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide Once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi: 10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–598. doi: 10.1016/S0140-6736(21)01443-4
   PubMed Web of Science ®Google Scholar
• Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–1824. doi: 10.1016/S0140-6736(21)02188-7
   PubMed Web of Science ®Google Scholar
• Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–545. doi: 10.1001/jama.2022.0078
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. doi: 10.1016/S0140-6736(23)01200-X
   PubMed Web of Science ®Google Scholar
• le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023;31(1):96–110. doi: 10.1002/oby.23612
   PubMed Web of Science ®Google Scholar
• Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/Topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6): doi: 10.1056/EVIDoa2200014
   Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–342. doi: 10.1038/oby.2011.330
   PubMed Web of Science ®Google Scholar
• Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (contrave): newly approved treatment option for chronic weight management in obese adults. P T. 2016;41(3):164–172. doi: 10.1001/jama.2014.732
   PubMedGoogle Scholar
• Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother. 2011;12(11):1813–1826. doi: 10.1517/14656566.2011.591382
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605. doi: 10.1016/S0140-6736(10)60888-4
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943. doi: 10.1002/oby.20309
   PubMed Web of Science ®Google Scholar
• Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029. doi: 10.2337/dc13-0234
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120. doi: 10.1038/oby.2010.147
   PubMed Web of Science ®Google Scholar
• Jeong D, Priefer R. Anti-obesity weight loss medications: short-term and long-term use. Life Sci. 2022;306:120825. doi: 10.1016/j.lfs.2022.120825
   PubMed Web of Science ®Google Scholar
• Grover A, Quaye E, Brychta RJ, et al. Leptin decreases energy expenditure despite increased thyroid hormone in patients with lipodystrophy. J Clin Endocrinol Metab. 2021;106(10):e4163–e4178. doi: 10.1210/clinem/dgab269
   PubMed Web of Science ®Google Scholar
• Hinney A, Korner A, Fischer-Posovszky P. The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. Nat Rev Endocrinol. 2022;18(10):623–637. doi: 10.1038/s41574-022-00716-0
   PubMed Web of Science ®Google Scholar
• Tsoukas MA, Farr OM, Mantzoros CS. Leptin in congenital and HIV-associated lipodystrophy. Metabolism. 2015;64(1):47–59. doi: 10.1016/j.metabol.2014.07.017
   PubMed Web of Science ®Google Scholar
• Ryan DH. Next generation antiobesity medications: setmelanotide, semaglutide, Tirzepatide and Bimagrumab: what do they mean for clinical practice? J Obes Metab Syndr. 2021;30(3):196–208. doi: 10.7570/jomes21033
   PubMed Web of Science ®Google Scholar
• Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83(24):2239–2246. doi: 10.1212/WNL.0000000000001070
   PubMed Web of Science ®Google Scholar
• Rooks DS, Laurent D, Praestgaard J, et al. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle. 2017;8(5):727–734. doi: 10.1002/jcsm.12205
   PubMed Web of Science ®Google Scholar
• Fournier B, Murray B, Gutzwiller S, et al. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol. 2012;32(14):2871–2879. doi: 10.1128/MCB.06575-11
   PubMed Web of Science ®Google Scholar
• Akpan I, Goncalves MD, Dhir R, et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). 2009;33(11):1265–1273. doi: 10.1038/ijo.2009.162
   PubMed Web of Science ®Google Scholar
• Garito T, Roubenoff R, Hompesch M, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diab Obes Metab. 2018;20(1):94–102. doi: 10.1111/dom.13042
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs placebo on body fat Mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457
   PubMed Web of Science ®Google Scholar
• Rooks D, Petricoul O, Praestgaard J, et al. Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J Cachexia Sarcopenia Muscle. 2020;11(6):1525–1534. doi: 10.1002/jcsm.12639
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Kaplan LM, FríFríAs JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972
   PubMed Web of Science ®Google Scholar
• Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160–2172. doi: 10.1016/S0140-6736(21)01751-7
   PubMed Web of Science ®Google Scholar
• Adeghate E, Kalasz H. Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J. 2011;5(Suppl 2):78–81. doi: 10.2174/1874104501105010078
   PubMedGoogle Scholar
• Sidik S. Beyond ozempic: brand-new obesity drugs will be cheaper and more effective. Nature. 2023;619(7968):19–19. doi: 10.1038/d41586-023-02092-9
   PubMed Web of Science ®Google Scholar
• Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877–888. doi: 10.1056/NEJMoa2302392
   PubMed Web of Science ®Google Scholar
• Leddy JJ, Epstein LH, Jaroni JL, et al. Influence of methylphenidate on eating in obese men. Obes Res. 2004;12(2):224–232. doi: 10.1038/oby.2004.29
   PubMedGoogle Scholar
• Levy LD, Fleming JP, Klar D. Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder. Int J Obes (Lond). 2009;33(3):326–334. doi: 10.1038/ijo.2009.5
   PubMed Web of Science ®Google Scholar
• Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906–1913. doi: 10.1016/S0140-6736(08)61525-1
   PubMed Web of Science ®Google Scholar
• Cowen N, Bhatnagar A. The potential role of activating the ATP-Sensitive potassium channel in the treatment of hyperphagic obesity. Genes (Basel). 2020;11(4). doi: 10.3390/genes11040450
   PubMed Web of Science ®Google Scholar
• Castellano JM, Ariza-Jimenez AB, Tena-Sempere M. New avenues for pharmacological management of hyperphagia and associated behavioral disorders in prader-willi syndrome. J Clin Endocrinol Metab. 2023;108(9):e895–e896. doi: 10.1210/clinem/dgad131
   PubMed Web of Science ®Google Scholar
• Miller JL, Gevers E, Bridges N, et al. Diazoxide choline extended-release tablet in people with prader-willi syndrome: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2023;108(7):1676–1685. doi: 10.1210/clinem/dgad014
   PubMed Web of Science ®Google Scholar
• Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med. 1997;23(2):302–313. doi: 10.1016/S0891-5849(97)00089-0
   PubMed Web of Science ®Google Scholar
• Choi LS, Jo IG, Kang KS, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int J Obes (Lond). 2021;45(1):130–142. doi: 10.1038/s41366-020-00686-1
   PubMed Web of Science ®Google Scholar
• Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160–184. doi: 10.1016/j.fitote.2013.07.003
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Kishida H, Arai N, et al. Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-A(y) mice. Biol Pharm Bull. 2004;27(11):1775–1778. doi: 10.1248/bpb.27.1775
   PubMed Web of Science ®Google Scholar
• Lee JW, Choe SS, Jang H, et al. AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity. J Lipid Res. 2012;53(7):1277–1286. doi: 10.1194/jlr.M022897
   PubMed Web of Science ®Google Scholar
• Aoki F, HONDA S, KISHIDA H, et al. Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Biosci Biotechnol Biochem. 2007;71(1):206–214. doi: 10.1271/bbb.60463
   PubMed Web of Science ®Google Scholar
• Ao M, Shi Y, Cui Y, et al. Factors influencing glabridin stability. Nat Prod Commun. 2010;5(12):1907–1912. doi: 10.1177/1934578X1000501214
   PubMed Web of Science ®Google Scholar
• Ito C, OI N, HASHIMOTO T, et al. Absorption of dietary licorice isoflavan glabridin to blood circulation in rats. J Nutr Sci Vitaminol (Tokyo). 2007;53(4):358–365. doi: 10.3177/jnsv.53.358
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. doi: 10.1016/j.molmet.2022.101633
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12):1729–1736. doi: 10.1038/sj.ijo.0803344
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390–2395. doi: 10.2337/diabetes.54.8.2390
   PubMed Web of Science ®Google Scholar
• Le Roux. 51-OR: a phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with Overweight/Obesity. Diabetes. 2023;72(Supplement_1): doi: 10.2337/db23-51-OR
   Google Scholar
• Turner A, Veysey M, Keely S, et al. Interactions between bitter taste, diet and Dysbiosis: consequences for appetite and obesity. Nutrients. 2018;10(10):1336. doi: 10.3390/nu10101336
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Zheng Z, Timmer A, et al. First-in-human evaluation of oral denatonium acetate (ARD-101), a potential bitter taste receptor agonist: a randomized, double-blind, placebo-controlled phase 1 trial in healthy adults. Clin Pharmacol Drug Dev. 2022;11(8):997–1006. doi: 10.1002/cpdd.1100
   PubMed Web of Science ®Google Scholar
• D’Urso O, Drago F. Pharmacological significance of extra-oral taste receptors. Eur J Pharmacol. 2021;910:174480. doi: 10.1016/j.ejphar.2021.174480
   PubMed Web of Science ®Google Scholar
• Senior M. After GLP-1, what’s next for weight loss? Nat Biotechnol. 2023;41(6):740–743. doi: 10.1038/s41587-023-01818-4
   PubMed Web of Science ®Google Scholar
• Liszt. Human intestinal bitter taste receptors regulate innate immune responses and metabolic regulators in obesity. J Clin Invest. 2022;132(3): doi: 10.1172/JCI144828
   PubMed Web of Science ®Google Scholar
• Khan AS, Hichami A, Murtaza B, et al. Novel fat taste receptor agonists curtail progressive weight gain in obese male mice. Cell Mol Gastroenterol Hepatol. 2023;15(3):633–663. doi: 10.1016/j.jcmgh.2022.11.003
   PubMed Web of Science ®Google Scholar
• Shimpukade B, Hudson BD, Hovgaard CK, et al. Discovery of a potent and selective GPR120 agonist. J Med Chem. 2012;55(9):4511–4515. doi: 10.1021/jm300215x
   PubMed Web of Science ®Google Scholar
• Douglas Braymer H, Zachary H, Schreiber AL, et al. Lingual CD36 and nutritional status differentially regulate fat preference in obesity-prone and obesity-resistant rats. Physiol Behav. 2017;174:120–127. doi: 10.1016/j.physbeh.2017.03.015
   PubMed Web of Science ®Google Scholar
• Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature. 2012;483(7389):350–354. doi: 10.1038/nature10798
   PubMed Web of Science ®Google Scholar
• Crunkhorn S. Metabolic disease: leptin sensitizer reverses obesity. Nat Rev Drug Discov. 2016;15(9):601. doi: 10.1038/nrd.2016.166
   PubMedGoogle Scholar
• Lee J, Liu J, Feng X, et al. Withaferin a is a leptin sensitizer with strong antidiabetic properties in mice. Nat Med. 2016;22(9):1023–1032. doi: 10.1038/nm.4145
   PubMed Web of Science ®Google Scholar
• Liu J, Lee J, Hernandez MA, et al. Treatment of obesity with celastrol. Cell. 2015;161(5):999–1011. doi: 10.1016/j.cell.2015.05.011
   PubMed Web of Science ®Google Scholar
• Chellappa K, Perron IJ, Naidoo N, et al. The leptin sensitizer celastrol reduces age-associated obesity and modulates behavioral rhythms. Aging Cell. 2019;18(3):e12874. doi: 10.1111/acel.12874
   PubMed Web of Science ®Google Scholar
• Cakir I, Lining Pan P, Hadley CK, et al. Sulforaphane reduces obesity by reversing leptin resistance. Elife. 2022;11:11. doi: 10.7554/eLife.67368
   Web of Science ®Google Scholar
• Ahangarpour A, Shabani R, Farbood Y. The effect of betulinic acid on leptin, adiponectin, hepatic enzyme levels and lipid profiles in streptozotocin-nicotinamide-induced diabetic mice. Res Pharm Sci. 2018;13(2):142–148. doi: 10.4103/1735-5362.223796
   PubMedGoogle Scholar
• Zhao S, Zhu Y, Schultz RD, et al. Partial leptin reduction as an insulin sensitization and weight loss strategy. Cell Metab. 2019;30(4):706–719.e6. doi: 10.1016/j.cmet.2019.08.005
   PubMed Web of Science ®Google Scholar
• Isoda M, Ebihara K, Sawayama N, et al. Leptin sensitizing effect of 1,3-butanediol and its potential mechanism. Sci Rep. 2021;11(1):17691. doi: 10.1038/s41598-021-96460-y
   PubMed Web of Science ®Google Scholar
• Yan C, Yang Y, Saito K, et al. Meta-chlorophenylpiperazine enhances leptin sensitivity in diet-induced obese mice. Br J Pharmacol. 2015;172(14):3510–3521. doi: 10.1111/bph.13141
   PubMed Web of Science ®Google Scholar
• Elfhag K, Rössner S, Carlsson AM, et al. Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. Obes Res. 2003;11(11):1391–1399. doi: 10.1038/oby.2003.188
   PubMedGoogle Scholar
• Rolls BJ, Shide DJ, Thorwart ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res. 1998;6(1):1–11. doi: 10.1002/j.1550-8528.1998.tb00308.x
   PubMedGoogle Scholar
• James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917. doi: 10.1056/NEJMoa1003114
   PubMed Web of Science ®Google Scholar
• Samanta D. Fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. Children (Basel). 2022;9(8). doi: 10.3390/children9081159
   Web of Science ®Google Scholar
• Weintraub M, Hasday JD, Mushlin AI, et al. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144(6):1143–1148. doi: 10.1001/archinte.1984.00350180055008
   PubMed Web of Science ®Google Scholar
• Robson PJ. Therapeutic potential of cannabinoid medicines. drug test anal. Drug Test Anal. 2014;6(1–2):24–30. doi: 10.1002/dta.1529
   PubMed Web of Science ®Google Scholar
• Dawson AJ, Kilpatrick ES, Coady AM, et al. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord. 2017;17(1):41. doi: 10.1186/s12902-017-0194-2
   PubMedGoogle Scholar
• Sathyapalan T, Cho L, Kilpatrick ES, et al. Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2010;72(3):423–425. doi: 10.1111/j.1365-2265.2009.03643.x
   PubMed Web of Science ®Google Scholar
• Sathyapalan T, Cho LW, Kilpatrick ES, et al. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clin Endocrinol (ox). 2009;70(1):124–128. doi: 10.1111/j.1365-2265.2008.03345.x
   Google Scholar
• Sathyapalan T, Cho LW, Kilpatrick ES, et al. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin Endocrinol (Oxf). 2008;69(6):931–935. doi: 10.1111/j.1365-2265.2008.03260.x
   PubMed Web of Science ®Google Scholar
• Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Braz J Psychiatry. 2009;31(2):145–153. doi: 10.1590/S1516-44462009000200012
   PubMed Web of Science ®Google Scholar
• Shukla AP, Kumar RB, Aronne LJ. Lorcaserin Hcl for the treatment of obesity. Expert Opin Pharmacother. 2015;16(16):2531–2538. doi: 10.1517/14656566.2015.1096345
   PubMed Web of Science ®Google Scholar
• Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387(10031):1947–1956. doi: 10.1016/S0140-6736(16)00271-3
   PubMed Web of Science ®Google Scholar
• Higgins GA, Fletcher PJ, Shanahan WR. Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther. 2020;205:107417. doi: 10.1016/j.pharmthera.2019.107417
   PubMed Web of Science ®Google Scholar
• Inoue S, Egawa M, Satoh S, et al. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am J Clin Nutr. 1992;55(1):199S–202S. doi: 10.1093/ajcn/55.1.199s
   PubMed Web of Science ®Google Scholar
• Slama G, Selmi A, Hautecouverture M, et al. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients. Diabete Metab. 1978;4(3):193–199.
   PubMed Web of Science ®Google Scholar